https://seekingalpha.com/article/4751968-humacyte-upside-potential-i-will-wait-for-revenue-trends [Seeking Alpha]
Humacyte, Inc. (HUMA)
Company Research
Source: Seeking Alpha
The company's precarious cash position, exacerbated by fundraising from Lincoln Park and other investors, hindered stock recovery. Symvess, priced at $29,500 per unit, offers a cost-effective alternative for vascular trauma, with high patency and low infection rates. I see potential upside as HUMA starts generating revenue and progresses with AV fistula approval, but financial risks and potential dilution remain. Richard Drury I started a position in Humacyte ( NASDAQ: HUMA ) in January 2023, and it was a decent investment for me as well as for TPT members. I exited my position after the approval of Symvess for vascular trauma, the effects About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring hands-on support, our in-hou
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]Yahoo! Finance
- Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma RepairGlobeNewswire
- Humacyte (NASDAQ:HUMA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HUMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 12/16/25 - Form 8-K
- 12/16/25 - Form 424B5
- 12/15/25 - Form 8-K
- HUMA's page on the SEC website